Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 8, 2025

Impact of the addition of antithymocyte globulin to post-transplantation cyclophosphamide in haploidentical transplantation with peripheral blood compared to post-transplantation cyclophosphamide alone: A retrospective study on behalf of the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation.

View Full Paper
Ask AI
Bookmark
Share

Authors

ACAntoine CapesJMJarl MooyaartDBDidier Blaise

Discussion

Loading...

Member takes

Overview

Retrospective analysis suggests adding antithymocyte globulin to post-transplant cyclophosphamide may reduce chronic graft-versus-host disease but worsen overall survival.

Key Points

  • Main finding indicates that adding antithymocyte globulin to post-transplant cyclophosphamide reduces chronic graft-versus-host disease.
  • Key evidence shows a significant difference in overall survival with HR = 1.18 (p = 0.037) in the PTcy+ATG group.
  • Approach involved analyzing data from 4,519 patients receiving PTcy only and 675 patients with PTcy+ATG over median 29.80 months.
  • Significance lies in understanding the balance between chronic graft-versus-host disease reduction and overall patient survival outcomes.

Cite This Study

Capes et al. (2025) studied this question.

synapsesocial.com/papers/689dfe97d61984b91e13be90https://doi.org/10.1111/bjh.70050
View Full Paper
Ask AI
Bookmark
Share